APMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Apnimed, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 8, 2026
$16.59−1.17 (-6.56%)
Close on Oct 19, 2026
- Market cap
- $536.90M
- P/E (TTM)
- –
- Dividend yield
- –
Apnimed statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Apnimed | Industry median |
|---|---|---|
| Market Cap | $79.69M | $166.30M |
| Enterprise Value | -$52.85M | $88.19M |
Balance sheet
| Measure | Apnimed | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $172.80M | $61.43M |
| Total Debt | $40.27M | $118.52M |
| Net Cash (Debt) | $132.54M | $15.35M |
| Net Cash Per Share | $27.60 | $0.66 |
| Equity (Book Value) | -$176.18M | $49.09M |
| Book Value Per Share | -$36.69 | $1.37 |
| Tangible Book Value | -$176.18M | $23.52M |
| Working Capital | $149.19M | $76.81M |
Financial position
| Measure | Apnimed | Industry median |
|---|---|---|
| Current Ratio | 5.19 | 3.34 |
| Quick Ratio | 4.88 | 2.44 |
Shares
| Measure | Apnimed | Industry median |
|---|---|---|
| Shares Outstanding | 4,801,820 | 58,127,000 |
Scores
| Measure | Apnimed | Industry median |
|---|---|---|
| Altman Z-Score | -0.16 | -0.22 |
Calculated by StockData from Apnimed's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.